Meet our SPARK Fellows

Introducing Cohort 8

zhirui_wang_500

Zhirui Wang, PhD

CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion

CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion

This project aims to overcome the immunosuppressive tumor microenvironment (TME) by targeting tumor-infiltrating effector Tregs, which hinder antitumor immune responses. The researchers have developed a novel CCR4 immunotoxin (CCR4-IT) to specifically deplete tumor-infiltrating Tregs for broad-spectrum cancer treatment. They plan to evaluate the efficacy of this immunotoxin using humanized mouse tumor models. The data generated from these studies will be utilized to secure further funding or attract commercial investment, with the ultimate goal of advancing this technology into clinical trials for Treg-targeted immunotherapy, potentially revolutionizing cancer treatment.

Learn more about Dr. Wang

Cohort 7

Jessica Rove, MD

Jessica Rove, MD

Colorado Chest Tube

Juan-Pablo Idrovo, MD

Juan-Pablo Idrovo, MD

Gastrostomy Tube Guardian

Rui Zhao, PhD

Rui Zhao, PhD

Developing a First-in-Class Allosteric Eya2 Tyrosine Phosphatase Inhibitor for Brain Cancer Therapy

Sujatha Venkataraman, PhD

Development of Gated Dual-antigen Targeting CAR-T Cell Therapy to Treat ATRT, an Aggressive Brain Tumor in Children

zhirui_wang_500

Zhirui Wang, PhD

Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia and Other CD47+ Cancers

Cohort 6

zhirui_wang_500

Zhirui Wang, PhD

CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion

CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion

This project aims to overcome the immunosuppressive tumor microenvironment (TME) by targeting tumor-infiltrating effector Tregs, which hinder antitumor immune responses. The researchers have developed a novel CCR4 immunotoxin (CCR4-IT) to specifically deplete tumor-infiltrating Tregs for broad-spectrum cancer treatment. They plan to evaluate the efficacy of this immunotoxin using humanized mouse tumor models. The data generated from these studies will be utilized to secure further funding or attract commercial investment, with the ultimate goal of advancing this technology into clinical trials for Treg-targeted immunotherapy, potentially revolutionizing cancer treatment.

Learn more about Dr. Wang

Cohort 5

zhirui_wang_500

Zhirui Wang, PhD

CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion

CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion

This project aims to overcome the immunosuppressive tumor microenvironment (TME) by targeting tumor-infiltrating effector Tregs, which hinder antitumor immune responses. The researchers have developed a novel CCR4 immunotoxin (CCR4-IT) to specifically deplete tumor-infiltrating Tregs for broad-spectrum cancer treatment. They plan to evaluate the efficacy of this immunotoxin using humanized mouse tumor models. The data generated from these studies will be utilized to secure further funding or attract commercial investment, with the ultimate goal of advancing this technology into clinical trials for Treg-targeted immunotherapy, potentially revolutionizing cancer treatment.

Learn more about Dr. Wang

Cohort 4

Cohort 3

Cohort 2

Cohort 1

CU Innovations

CU Anschutz

Anschutz Health Sciences Building

1890 N Revere Ct

Suite 6202

Mail Stop F411

Aurora, CO 80045


303-724-3720

CMS Login